Xaga Surgical wins FDA clearance for prostate biopsy needle, raises SEK 17M
What's the deal? Xaga SurgicalDealroom has a profile for this one. Try Dealroom →, a Swedish medical technology company, has won FDA 510(k) clearance for a redesigned prostate biopsy needle that it says cuts bacterial transmission by up to 96%. The company has also raised SEK 17 million (about $1.6M) in growth equity from existing owners and investors, including SmiLe Inject CapitalDealroom has a profile for this one. Try Dealroom → and Almi Invest.
The needle is already in clinical use at several US centres, including Penn State College of Medicine. The fresh capital will fund wider rollout across American specialist clinics, boost production capacity, and prepare for European market entry.
Why now? Millions of prostate biopsies are performed worldwide each year, and roughly 3% cause serious complications such as infections or injuries. The standard needle design is more than 50 years old.
Xaga's instrument follows a straighter path to the sample area, improving precision while reducing the infection risk. European CE marking is expected in 2026, which would open a second major market.
"I have seen many men suffer from infections after prostate cancer biopsies with today's biopsy needle design," said Andreas ForsvallDealroom has a profile for this one. Try Dealroom →, senior physician in urology and founder of Xaga Surgical. "The FDA approval and the fact that leading American centres are already using our technology are important validations."
What could go wrong? The company is early-stage and small — it has previously raised SEK 30 million in total. Competing against entrenched incumbents in a procedure performed millions of times a year will require significant commercial muscle that $1.6M alone may not provide.
Regulatory timelines for European approval could slip. And convincing hospitals to switch from a familiar, decades-old standard demands robust clinical evidence and reimbursement support.
The signal: With total funding of roughly SEK 47 million and an early-stage profile, Xaga Surgical is a bet that simple hardware redesigns in legacy medical devices can command outsized value — especially when tied to the growing global urgency around antibiotic resistance. The backing of repeat investors SmiLe Inject Capital and Almi Invest suggests confidence in the commercial path, but scaling a single-product medtech company against entrenched incumbents in a procedure performed millions of times a year will likely require a significantly larger funding round ahead of European launch.
Read more: UroToday
